
==== Front
Infect Dis Ther
Infect Dis Ther
Infectious Diseases and Therapy
2193-8229
2193-6382
Springer Healthcare Cheshire

39230828
1035
10.1007/s40121-024-01035-9
Case Series
Mycoplasma hominis as Cause of Extragenital Infection in Patients with Hypogammaglobulinemia: Report of 2 Cases and Literature Review
Russo Chiara 12
Mikulska Malgorzata m.mikulska@unige.it

12
Delfino Emanuele 2
Toscanini Federica 2
Mezzogori Laura 12
Schiavoni Riccardo 12
Bartalucci Claudia 12
Angelucci Emanuele 3
Bartalucci Giulia 3
Gambella Massimiliano 3
Raiola Anna Maria 3
Morici Paola 4
Crea Francesca 4
Chiola Silvia 5
Morbelli Silvia Daniela 5
Marchese Anna 4
Bassetti Matteo 12
1 https://ror.org/0107c5v14 grid.5606.5 0000 0001 2151 3065 Division of Infectious Diseases, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
2 https://ror.org/04d7es448 grid.410345.7 0000 0004 1756 7871 Infectious Diseases Unit, IRCCS Ospedale Policlinico San Martino, L.Go R. Benzi, 10, 16132 Genoa, Italy
3 https://ror.org/04d7es448 grid.410345.7 0000 0004 1756 7871 Hematology and Transplant Center, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
4 https://ror.org/04d7es448 grid.410345.7 0000 0004 1756 7871 Microbiology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
5 https://ror.org/04d7es448 grid.410345.7 0000 0004 1756 7871 Nuclear Medicine Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
4 9 2024
4 9 2024
10 2024
13 10 21792193
28 5 2024
16 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Mycoplasma hominis can be a part of human urogenital tract microbiome, and it is a frequent cause of urogenital infections. In rare cases, it can also cause extragenital infections, especially in immunocompromised patients. In this case series, we report two cases and provide a literature review of extragenital infections caused by M. hominis in patients with hypogammaglobulinemia. Patient 1 was a 61-year-old woman with diffuse large B-cell lymphoma who, after rituximab-containing chemotherapy and CAR-T therapy, developed M. hominis spondylodiscitis. Patient 2 was a 50-year-old woman with congenital hypogammaglobulinemia who developed disseminated M. hominis infection involving pleura, muscles, and right ankle. Antibiotic therapy with levofloxacin and doxycycline for 10 weeks in patient 1 and with levofloxacin alone for 6 weeks in patient 2 led to infection resolution. The literature review identified 14 additional cases reporting M. hominis extragenital infection in patients with hypogammaglobulinemia. M. hominis should also be suspected as an etiological agent of extragenital infection in patients with B-cell immunodeficiency with a clinical picture of persistent, standard-culture negative infection, particularly with arthritis or abscess formation. Even if M. hominis can grow on standard bacterial medium, in suspected cases molecular methods should be promptly used for correct diagnostic work-up and successful therapy.

Keywords

Extragenital infection
Hypogammaglobulinemia
Mycoplasma hominis
issue-copyright-statement© Springer Healthcare Ltd., part of Springer Nature 2024
==== Body
pmcKey Summary Points

Mycoplasma hominis can cause serious disseminated extragenital infections in patients with hypogammaglobulinemia, also after B-cell-depleting therapies including CAR-T.	
In patients with disseminated infection in which no pathogen grows on common culture media, Mycoplasmataceae should be considered and specific testing performed with molecular methods and selective culture media.	
Doxycycline, azithromycin, and fluoroquinolone, in monotherapy or in combination, have been successfully used in 13 of 15 cases identified through literature review.	
In our two cases, diagnosis was obtained thanks to biopsies cultured on standard media, and PET-CT scan was used to guide the length of therapy.	

Introduction

Mycoplasma spp. is a member of the Mycoplasmataceae family, class Mollicutes [1, 2]. M. hominis can be found in the vagina or cervix in approximately 20–50% of sexually mature women [3]. It is part of the normal human urogenital tract microbiome, where it resides on the mucosal surface [4].

In the male and female genital tract, M. hominis can be either a colonizing pathogen or the causal agent of infections, such as urethritis, bacterial vaginosis, cervicitis, and pelvic inflammatory syndrome. M. hominis can also be associated with infertility in both men and women [1]. Given the high rate of colonization, screening in asymptomatic men and women for Mycoplasma spp. is not recommended, and testing should be performed only in cases of symptoms of genital infection [5–7].

Although rare, extragenital infections due to M. hominis have been reported, especially in immunocompromised patients. They comprise mediastinitis, septic arthritis, osteomyelitis, prosthetic joint infection following surgery and trauma, abscess after transplant or surgical procedures, central nervous system infections (mainly post-surgical and post-trauma brain abscess or meningitis), infective endocarditis, and bacteremia [1]. The first three reported series of extragenital M. hominis infections by Madoff et al. in 1988 [8], McMahon in 1990 [9], and Meyer et al. in 1993 [10] reviewed 36, 13, and 67 cases, respectively. They found that the main risk factor for extragenital infection was immunosuppression, followed by surgery, trauma, and other conditions. Among 32 patients with immunosuppression, two had hypogammaglobulinemia, both due to congenital deficiency [10]. Other authors confirmed that Mycoplasma spp. could be a frequent cause of infection in patients with hypogammaglobulinemia, but most of the infections were respiratory and species other than M. hominis (mainly M. pneumonia) were detected [11].

In this report, we want to focus on extragenital M. hominis infections in patients with hypogammaglobulinemia, also caused by recently introduced therapeutic options such as CAR-T therapy, reporting two cases from our center and providing a literature review.

Cases Description

Case 1

A 61-year-old woman with diffuse large B cell lymphoma underwent eight cycles of first-line plus three cycles of second-line chemotherapy; both first- and second-line regimens included rituximab. As after chemotherapy she experienced disease progression, she underwent chimeric antigen receptor T cell therapy (CAR-T with Yescarta®) on 11/08/2021 (day 0). Of note, as comorbidity she had severe osteoporosis complicated by multiple vertebral fractures.

On day + 20, the patient complained about lumbar pain, first ascribed to multiple already known fractures. At that time, her immunoglobulin level was low [IgG 2.200 g/L (normal value 8.000–17.000), IgA 0.225 g/L (normal value 0.700–4.000), IgM 0.031 g/L (normal value 0.400–2.300)] as a consequence of prolonged rituximab therapy.

On day + 30, she underwent fluorodeoxyglucose–positron emission tomography (FDG-PET) study (Fig. 1), which showed complete metabolic response in sites of lymph nodal disease but revealed elevated high tracer uptake at the first (L1) and second (L2) lumbar vertebrae [standardized uptake value (SUV) max 16.2]. On day + 42, lumbar magnetic resonance imaging (MRI) was performed, showing structural disruption by pathological tissue at multiple levels and suspected pathological fracture at L1–L2. On day + 49, vertebral biopsy and vertebroplasty were performed. Histological examination revealed inflammation and excluded neoplastic process. Biopsy culture grew M. hominis on sheep blood agar plates and identification was performed with matrix-assisted laser desorption–ionization time of flight (MALDI-TOF) after 2 days of incubation at 37 °C in aerobic conditions. Considering histological characteristics and microbiological results, on day + 56, levofloxacin 750 mg every 24 h plus doxycycline 100 mg every 12 h were prescribed.Fig. 1 Baseline (A) and control (B) PET performed in the first patient. A FDG baseline PET performed before the start of antibiotic therapy; arrows mark tracer hyperaccumulation at the soma of the L1 and L2 vertebrae (SUV max 16.2). B control PET performed after 8 weeks of antibiotic therapy; tracer hyperaccumulation no longer evident at L2 soma level

Polymerase chain reaction (PCR) (day + 59) for Mycoplasmataceae showed urinary and vaginal colonization by M. hominis and Ureaplasma urealyticum, not associated with genital symptoms of infection. Since Mycoplasma can cause infections of cell cultures, we reviewed the summary of critical quality attributes of the patient’s CAR-T product and found that it had tested negative by PCR for Mycoplasma spp.

A follow-up FDG-PET performed after 3 and 8 (Fig. 1B) weeks of antibiotic therapy documented first reduction and later almost complete resolution of spondylodiscitis, with FDG hyperaccumulation no longer evident at L2 soma, but the relapse of lymphoma was present. PCR search of Mycoplasmataceae was negative for M. hominis and U. urealyticum on both urine and vaginal swabs (day + 88).

The combination antibiotic therapy for Mycoplasma spondylodiscitis with levofloxacina and doxycycline was well tolerated but interrupted at 10 weeks (instead of the planned 12 weeks), as the patient expired due to lymphoma progression on day + 128 after CAR-T therapy.

Case 2

A 50-year-old woman with congenital hypogammaglobulinemia (previously on replacement therapy) presented at the Emergency Department with a 3-month history of malaise, asthenia, back pain, and ankle pain. She was admitted to a different hospital (day 0, 27/12/2022), where she underwent several radiological assessments that revealed multiple abscesses localized in pelvic and perineal muscles (the largest 5 × 8 × 1.6 cm), pleural empyema, and right ankle arthritis. All the cultures performed (of blood, pleural liquid, glute abscess fluid, hip arthrocentesis fluid, and ankle arthrocentesis fluid) came up negative. At that time, all the immunoglobulin classes were below the lower limit of detection since the patients had not recieved immunoglobulin replacement therapy for several months.

As fever, pain, and inflammation persisted, empirical broad-spectrum antimicrobial therapy was started: first, with daptomycin plus metronidazole and meropenem, and then with ceftaroline, fosfomycin, ceftolozane/tazobactam and caspofungin.

Clinical conditions did not improve and generalized malaise with fever persisted. The patient was therefore transferred to our regional reference center for infectious diseases (day + 42), where antimicrobial therapy was discontinued. Cultures of purulent wounds (localized at the site where previous thoracic and gluteal drainages were placed) were performed: all three grew M. hominis after 3 days of incubation (day + 45); molecular analyses through PCR of thoracic wound sample confirmed the presence of M. hominis (day + 45).

PCR screening for Mycoplasmataceae (day + 52) showed urine colonization by U. urealyticum and rectal colonization by M. hominis, not associated with local symptoms of infection.

Based on microbiological findings, on day + 45, levofloxacin 750 mg every 24 h was started.

A baseline FDG-PET performed on day + 48 (Fig. 2) showed high tracer uptake within the organized pleural effusion (SUV max 8), pelvic abscesses (SUV max 11), and right tibia-calcaneal joint (SUV max 8). As the patient was persistently confused since her admission, a brain MRI was performed (day + 51), showing mild signal hyperintensity in T1 along the profile of supratentorial ventricular system, suspected of micro-abscess. The cerebrospinal fluid chemical-physical analysis (day + 58) was significant only for moderate damage of blood–brain, while culture and PCR for Mycoplasmataceae were negative.Fig. 2 Baseline (A) and control (B) PET performed in the second patient. A Baseline PET performed before the start of antibiotic therapy. High tracer uptake in pelvis (A1), at internal obturator muscles of both sides (A2) and on the left extending to the external obturator muscle and great adductor muscle (A3) (SUV max 11). Concomitant high FDG uptake at the right tibio-calcaneal joint extending to the lateral aspect of the calcaneus and plantar region (A4) (SUV max 8). B Control PET performed after 6 weeks of antibiotic therapy. Marked reduction in size and hypermetabolism compared with previous control and suspicious for proportion of active disease at pelvis (B1). Residual modest tracer hyperaccumulation at the internal obturator muscles (B2) and external obturator muscle and great adductor muscle (B3) (SUV max 5). These findings are reported as borderline regarding diagnostic significance. No more significant accumulation evident at the right tibio-calcaneal joint (B4)

The fever resolved after 72 h of levofloxacin therapy, and ankle pain and swelling improved rapidly. Levofloxacin was continued for a total of 6 weeks, after which (day + 84) persistent rectal colonization by M. hominis was documented, while U. urealyticum was no longer detected in urine.

A second FDG-PET performed at the end of antibiotic therapy (day + 90) (Fig. 2) revealed the marked reduction of tracer uptake in the internal, external, and great adductor muscles (sites of pelvic abscesses at baseline, SUV max 5), and complete resolution of uptake in the ankle. During subsequent hospital admissions a year later, there was no relapse of M. hominis infection.

Microbiological culture records from out institution from the years 2014–2023 did not reveal any additional cases of extragenital M. hominis infection.

Literature Review

In Table 1, we summarize our 2 and 14 previously reported clinical cases of extragenital M. hominis infections in patients with hypogammaglobulinemia. We have included clinical cases reporting data on the cause of hypogammaglobulinemia, age, sex, diagnosis, treatment, and outcomes, obtained through a MEDLINE search with the keywords Mycoplasma, hypogammaglobulinemia, CAR-T, HSCT, rituximab, and anti-CD20 was performed. Papers’ references were screened for additional cases. Table 1 Extragenital Mycoplasma hominis infections in patients with hypogammaglobulinemia

No	First author, year of publication, country	Age (years)/sex	Underling condition associated with hypogammaglobulinemia	Clinical presentation	Diagnostic method, specimen	Antimicrobial treatment	Treatment duration	Outcome	
1	McMahon et al. 1990, USA [9]	63/M	Chronic lymphocytic leukemia, diabetes

Low-dose steroids

	Right knee arthritis	Culture on standard medium

Synovial fluid

	Clindamycin plus tetracycline	4 weeks	Alive, but knee fusion was required	
2	Steuer et al., 1996, UK [35]	42/F	CVID	Arthritis	Culture on selective medium (inconclusive culture on common medium)

Synovial fluid

	Erythromycin plus tetracycline, plus surgery	Long term	Improvement but not complete resolution	
3	Franz et al. 1997, UK [36]	47/F	CVID	Left knee and first metacarpal phalangeal joint arthritis	Culture on selective medium (inconclusive culture on common medium)

Synovial fluid

	Doxycycline	6 months	Resolution	
4	Franz et al. 1997, UK [36]	42/F	CVID	Bilateral knees, right hip, shoulders, wrists, ankles arthritis and subcutaneous nodules	Culture on selective medium (inconclusive culture on common medium)

Synovial fluid

	Ciprofloxacin plus clindamycin i.v.b	Not reported	Relapse	
Oral sparfloxacin	6 weeks	Permanent damage	
5	Heilmann et al., 2001, UK [37]	34/F	CVID	Prosthetic knee septic arthritis	Culture on standard medium

Joint fluid

	Doxycycline	3 months	Resolution	
6	Sendi et al., 2004, Switzerland [38]	48/F	Primary hypogammaglobulinemia	Pleuropneumonia, spondilitis and septic arthritis of the right knee	PCR and culture on standard medium (after several negative cultures of other samples on common media)

Synovial fluid

	Doxycycline	Not reported	Improvement	
7	MacKenzie et al., 2010, Germany [39]	54/M	NHL,

Rituximab therapy

	Knees and hip arthritis complicated by aortic aneurysm	PCR (16S) and culture on selective medium (inconclusive culture on common medium)

Aortal tissue biopsy and hip biopsya

	Moxifloxacin	14 days, until death	Death (septic shock, suspected hospital acquired infection)	
8	Wynes et al., 2013 [40]	33/M	X-linked agammaglobulinemia	Ankle arthritis	16S rRNA

Synovial fluid

	Doxycycline plus moxifloxacin	8 weeks	Resolution	
9	Sato et al., 2012, Japan [41]	26/M	Polyarthritis mimicking a RA and hypogammaglobulinemia of unknown origin	PIP, shoulder, knees, hip arthritis	16S rRNA and culture on selective medium (inconclusive culture on common medium)

Synovial fluid

	Not reported	Not reported	Death	
10	Nulens et al., 2016, Belgium [42]	61/M	NHL,

Rituximab therapy

	Chronic prostatitis, abscesses in the recto-vesical region, in adductor and gluteal muscles of the right hip; skin nodules on both arms	PCR (16S) and culture on selective medium (inconclusive culture on common medium)

Skin, urine, para-rectal abscess, right hip, and adductor muscle biopsy

	Moxifloxacin plus clindamycin plus drainage	Not reported	Resolution	
11	Ali et al., 2021, Qatar [43]	30/M	Refractory thrombotic thrombocytopenic purpura,

Rituximab therapy

	Left hip septic arthritis and iliopsoas abscess	Culture on standard medium confirmed by PCR

Synovial fluid

	Moxifloxacin plus tigecycline

Moxifloxacin plus doxycycline

	3 weeks

6–8 weeks

	Initial improvement after 3 weeks, then lost to follow up	
12	Stabler et al., 2021, USA [20]	55/F	RA,

Rituximab therapy

	Perirectal abscess with rectal perforation	Culture (pinpoint-sized colonies on standard medium → culture on selective medium)

Perirectal abscess fluid

	Doxycycline	3 weeks	Resolution	
13	Bozo et al., 2021, Denmark [44]	58/F	RA and UC,

Rituximab therapy

	Right hip and right knee septic arthritis	PCR (16S) and culture on selective medium (inconclusive culture on common medium)

Hip and knee synovial fluid

	Moxifloxacin plus doxycycline	8 weeks	Resolution	
14	Sadhar et al., 2022, USA [45]	24/M	Multiple sclerosis,

Rituximab therapy

	Acute otitis media complicated by facial paralysis	Culture on standard medium

Tympanic membrane biopsy

	Clindamycin i.v. plus oral doxycycline	Not reported	Improvement	
15	Reported here case 1	61/F	NHL,

Rituximab therapy and CAR-T

	Spondylodiscitis	Culture on standard medium

Vertebral biopsy

	Doxycycline plus levofloxacin	10 weeks	Resolution	
16	Reported here case 2	50/F	CVID	Right ankle arthritis, muscles abscesses, pleural empyema	Culture on standard medium

Purulent drainage

	Levofloxacin	6 weeks	Resolution	
Total, n = 16	Median 47.5

Range (24–63)

F 50%

	Rituximab therapy, n = 7 (+ CAR-T in 1)

CVID, n = 5

Other, n = 4

	Arthritis, n = 13

Abscess, n = 4

	Positive culture, n = 14

Standard medium, n = 7/14

	Combination therapy, n = 9

Tetracycline, n = 11

Fluoroquinolone, n = 8

	Median 8 weeks in patients with resolved infection

Range (2–24 weeks)

	Improvement/ resolution, n = 13/16	
M male, F female, CVID common variable immunodeficiency, NHL non-Hodgkin lymphoma, NA not available, PIP proximal interphalangeal joints, RA rheumatoid arthritis, UC ulcerative colitis, PCR polymerase chain reaction, i.v. intravenous

aM. hominis and U. parvum

b Resistance to tetracyclines detected

There was a similar distribution of iatrogenic and congenital causes of hypogammaglobulinemia (7 vs. 8). There was an osteoarticular involvement in 13 cases and the presence of abscesses in 4 cases. In 7 cases, M. hominis grew on a standard medium and diagnosis was confirmed by PCR or culture in selective medium, while a common medium culture was negative in the other 9, and diagnosis was made by culture on selective media or PCR.

Combination therapy was administered in 8 patients. Improvement or total resolution was obtained in 13 patients after a median length of treatment of 8 weeks, relapse occurred in 1 patient treated with combination therapy, and 2 patients died early.

Discussion

We have described two cases of severe extragenital infections due to M. hominis in patients with hypogammaglobulinemia, and we report the first case of M. hominis osteoarticular infection in a patient after CAR-T cell therapy. Indeed, a single case of lethal hyperammonemia related to Ureaplasma pneumonia in a CAR-T cell recipient has been reported, but no data on immunoglobulin levels were provided and no other cases of severe infections by the Mycoplasmataceae family heve been reported in CAR-T recipients [12].

Hypogammaglobulinemia can be associated with congenital (primary) [13, 14] or acquired (secondary) immunodeficiencies, such as drug-induced. Rituximab, which is a monoclonal antibody targeting the CD20 antigen expressed on B cells, can cause hypogammaglobulinemia usually for more than 6 months after administration [15]. In the 16 reported cases, the distribution of primary and secondary cases was almost equal.

It has been demonstrated that patients with hypogammaglobulinemia are more susceptible to Mycoplasma spp. mucosal colonization, and this could be explained by the lack of protective antibodies on the mucosal surface [13]. The possible higher mucosal colonization rate along with the lack of antibodies may also explain the increased risk of disseminated infection originating from urogenital tract in these patients [13, 16]. Regarding arthritis, in vitro study has suggested how a minor joint trauma can attract neutrophils that, in the absence of specific antibodies, can uptake Mycoplasma spp. into phagocytic vacuoles, which can be released into joint spaces leading to septic arthritis [17–19].

Both our patients had an osteoarticular involvement (in the second case, associated with other localizations of infection). This is in line with the literature (Table 1), in which osteoarticular involvement was reported in 81% of cases, confirming Mycoplasma spp. tropism for the joint.

In 7 of 16  identified cases (Table 1), diagnosis was made by culture on common media. This was possible since M. hominis is the only human-pathogenic species of Mycoplasma able to grow on blood or chocolate agar [20]. In our cases, as probably also in many others, the growth of M. hominis on a common culture medium was a stroke of luck, since we did not suspect Mycoplasma to be the possible cause of infection. In the absence of clinical suspicion, the difficulty in growth on common culture medium of other members of the Mycoplasmataceae family may lead to the underdiagnosis of infections due to these microorganisms. Indeed, the diagnosis of most Mycoplasma infections requires specific tests and the use of selective media for isolating Mycoplasma from clinical samples. Mycoplasma isolation in culture is often challenging due to the slow growth of small colonies. These microorganisms should be suspected if the isolate grows on agar medium in pinpoint-sized colonies (diameter, 0.2 mm) after 2–7 days of incubation and the Gram stain is negative (due to the lack of cell walls) [20]. Identification to the species level can obtained using MALDI-TOF [21]. Molecular methods, like PCR, provide an alternative for diagnosis of Mycoplasma spp. infections, both genital and extragenital. PCR allows the diagnosis of the disease by detecting the organism directly from clinical samples, and can also be used to identify suspect colonies [22]. The sensitivity and specificity of culture on selective media are reported to be 70% and 100%, respectively; the sensitivity of culture on common media is even lower. Compared to selective culture methods, PCR has demonstrated a sensitivity of 87–96% and a specificity of 87–100%, depending on the site of sample collection [23, 24]. Other diagnostic tests such as serology and cold agglutinins are no longer used.

Because Mycoplasma lacks a cell wall, it is intrinsically resistant to all antibiotics targeting the cell wall, such as ß-lactams [20]. Guidelines for the treatment of genital infection recommend doxycycline or azithromycin as first-line therapy [25–27], while fluoroquinolone and clindamycin are alternative therapeutic options. However, no recommendations on the treatment of extragenital infections are available, in particular on the use of monotherapy versus combination therapy or on the length of treatment in immunocompromised patients or in case of osteo-articular involvement.

In the identified cases (Table 1), combination therapy was preferred in 9 of 15 cases with data available (56%), and only one case of relapse was reported in a patient treated with a combination therapy. Combination therapy might be preferable in case of multi-organ involvement or when susceptibility testing results are not available, due to the possibility of infection by resistant strains. In particular, in studies performed around 2010, 10% of M. hominis strains were found to be resistant to doxycycline, 98% to azithromycin, and 8% to ciprofloxacin. Among fluoroquinolones, moxifloxacin demonstrated better in vitro activity against the Mycoplasmataceae compared to other molecules of the same antibiotic class [28, 29].

The length of antibiotic therapy varied significantly, from 3 weeks to long-term therapy (Table 1), but the median length of therapy in successfully treated patients was 8 weeks. In our cases, PET-CT scan at baseline and during treatment was performed to guide its length, as suggested in spondylodiscitis and other infectious settings [30, 31].

In our cases, we preferred a combination therapy of levofloxacin and doxycycline in the first patient considering severe immunodeficiency after CAR-T and bone involvement, while, in the second, less immunocompromised, patient with soft tissue infection and possible arthritis, monotherapy with levofloxacin was successfully administered. The length of therapy was 10 weeks in the first patient and 6 weeks in the second, with PET-CT scan negative after 8 and 6 weeks of therapy, respectively.

The limitations of our paper include the retrospective identification of the cases and the long observation period (from 1981 to 2023) of identified cases. Moreover, among causes of immunosuppression, we focused only on patients with reported hypogammaglobulinemia, which might also have been present but not reported in other immunocompromised patients. For instance, in recent papers of the importance of M. hominis and Ureaplasma respiratory infections in lung transplant recipients, a high rate of respiratory infections with Mollicutes was reported, but no data on IgG levels were provided [32–34].

Conclusion

Although it has been reported since 1980 that patients with hypogammaglobulinemia are at increased risk of infections caused by atypical pathogens like the Mycoplasmataceae, it is surprising that only a few cases of extragenital M. hominis infections have been reported in the last decades, despite an increase in B cell-depleting therapies, including CAR-T. Underdiagnosis might play a significant role as demonstrated by the fact that half of the cases were diagnosed thanks to positive results of cultures performed on standard media. Therefore, it is important that, in patients with hypogammaglobulinemia and persistent infections, particularly if disseminated or with bone/joint involvement, and negative standard culture, Mycoplasma infections are suspected. In such cases, molecular methods should be promptly used for correct diagnostic work-up and successful therapy. Prospective studies with molecular diagnostic protocols might provide much needed insight into the incidence of such infections.

Author Contributions

Chiara Russo, Malgorzata Mikulska, Paola Morici, Francesca Crea, Silvia Chiola, performed research and wrote the manuscript. Emanuele Delfino, Federica Toscanini, Laura Mezzogori, Riccardo Schiavoni, Claudia Bartalucci, Giulia Bartalucci, Massimiliano Gambella performed data collection. Emanuele Angelucci, Anna Maria Raiola, Silvia Daniela Morbelli, Anna Marchese, Matteo Bassetti supervised the study. All authors reviewed and approved the manuscript.

Funding

No funding or sponsorship was received for this study or publication of this article.

Data availability

The data that support the findings of this study are available on request from the corresponding author (MM).

Declarations

Conflict of Interest

Matteo Bassetti received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events of Angelini, Cidara, Gilead, Menarini, MSD, Pfizer, Shionogi, Multipharma. MB participated on a Data Safety Monitoring Board or Advisory Board with Angelini, Cidara, Gilead, Menarini, MSD, Pfizer, Shionogi, Multipharma. Malgorzata Mikulska is an Editorial Board member of Infectious Diseases and Therapy and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Chiara Russo, Emanuele Delfino, Federica Toscanini, Laura Mezzogori, Riccardo Schiavoni, Claudia Bartalucci, Emanuele Angelucci, Giulia Bartalucci, Massimilano Gambella, Anna Maria Crea, Paolo Morici, Francesca Crea, Silvia Chiola, Silvia Daniela Morbelli, and Anna Marchese have no conflicts of interest to declare.

Ethical Approval

The study was conducted in accordance with the Declaration of Helsinki. Both patients signed an institutional consent form which includes the use of electronic medical records and the conservation of biological samples for scientific purposes. Specific consent was obtained from the surviving patient.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Chiara Russo and Malgorzata Mikulska contributed equally to the manuscript.
==== Refs
References

1. Ahmed J Mycoplasma hominis: an under recognized pathogen Indian J Med Microbiol 2021 39 1 88 97 10.1016/j.ijmmb.2020.10.020 33610259
Ahmed J, et al. Mycoplasma hominis: an under recognized pathogen. Indian J Med Microbiol. 2021;39(1):88–97.33610259
2. Pettersson B Updated phylogenetic description of the Mycoplasma hominis cluster (Weisburg et al. 1989) based on 16S rDNA sequences Int J Syst Evol Microbiol 2000 50 Pt 1 291 301 10.1099/00207713-50-1-291 10826816
Pettersson B, et al. Updated phylogenetic description of the Mycoplasma hominis cluster (Weisburg et al. 1989) based on 16S rDNA sequences. Int J Syst Evol Microbiol. 2000;50 Pt 1:291–301.10826816
3. Taylor-Robinson D Mollicutes in vaginal microbiology: Mycoplasma hominis, Ureaplasma urealyticum, Ureaplasma parvum and Mycoplasma genitalium Res Microbiol 2017 168 9–10 875 881 10.1016/j.resmic.2017.02.009 28263902
Taylor-Robinson D. Mollicutes in vaginal microbiology: Mycoplasma hominis, Ureaplasma urealyticum, Ureaplasma parvum and Mycoplasma genitalium. Res Microbiol. 2017;168(9–10):875–81.28263902
4. Bennett JE Dolin R Blaser MJ Mandell, Douglas, and Bennett’s principles and practice of infectious diseases 2019 9 Amsterdam Elsevier
Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases, vol. 2. 9th ed. Amsterdam: Elsevier; 2019.
5. Horner P Should we be testing for urogenital Mycoplasma hominis, Ureaplasma parvum and Ureaplasma urealyticum in men and women?—a position statement from the European STI Guidelines Editorial Board J Eur Acad Dermatol Venereol 2018 32 11 1845 1851 10.1111/jdv.15146 29924422
Horner P, et al. Should we be testing for urogenital Mycoplasma hominis, Ureaplasma parvum and Ureaplasma urealyticum in men and women?—a position statement from the European STI Guidelines Editorial Board. J Eur Acad Dermatol Venereol. 2018;32(11):1845–51.29924422
6. Leli C Prevalence of cervical colonization by Ureaplasma parvum, Ureaplasma urealyticum, Mycoplasma hominis and Mycoplasma genitalium in childbearing age women by a commercially available multiplex real-time PCR: an Italian observational multicentre study J Microbiol Immunol Infect 2018 51 2 220 225 10.1016/j.jmii.2017.05.004 28711440
Leli C, et al. Prevalence of cervical colonization by Ureaplasma parvum, Ureaplasma urealyticum, Mycoplasma hominis and Mycoplasma genitalium in childbearing age women by a commercially available multiplex real-time PCR: an Italian observational multicentre study. J Microbiol Immunol Infect. 2018;51(2):220–5.28711440
7. Plummer EL Are Mycoplasma hominis, Ureaplasma urealyticum and Ureaplasma parvum associated with specific genital symptoms and clinical signs in nonpregnant women? Clin Infect Dis 2021 73 4 659 668 10.1093/cid/ciab061 33502501
Plummer EL, et al. Are Mycoplasma hominis, Ureaplasma urealyticum and Ureaplasma parvum associated with specific genital symptoms and clinical signs in nonpregnant women? Clin Infect Dis. 2021;73(4):659–68.33502501
8. Madoff S Hooper DC Nongenitourinary infections caused by Mycoplasma hominis in adults Rev Infect Dis 1988 10 3 602 613 10.1093/clinids/10.3.602 3293162
Madoff S, Hooper DC. Nongenitourinary infections caused by Mycoplasma hominis in adults. Rev Infect Dis. 1988;10(3):602–13.3293162
9. McMahon DK Extragenital Mycoplasma hominis infections in adults Am J Med 1990 89 3 275 281 10.1016/0002-9343(90)90338-E 2203260
McMahon DK, et al. Extragenital Mycoplasma hominis infections in adults. Am J Med. 1990;89(3):275–81.2203260
10. Meyer RD Clough W Extragenital Mycoplasma hominis infections in adults: emphasis on immunosuppression Clin Infect Dis 1993 17 Suppl 1 S243 S249 10.1093/clinids/17.Supplement_1.S243 8399923
Meyer RD, Clough W. Extragenital Mycoplasma hominis infections in adults: emphasis on immunosuppression. Clin Infect Dis. 1993;17(Suppl 1):S243–9.8399923
11. Roifman CM Increased susceptibility to Mycoplasma infection in patients with hypogammaglobulinemia Am J Med 1986 80 4 590 594 10.1016/0002-9343(86)90812-0 3963038
Roifman CM, et al. Increased susceptibility to Mycoplasma infection in patients with hypogammaglobulinemia. Am J Med. 1986;80(4):590–4.3963038
12. Tawfik P Arndt P Lethal hyperammonemia in a CAR-T cell recipient due to ureaplasma pneumonia: a case report of a unique severe complication BMJ Case Rep 2021 14 7 e242513 10.1136/bcr-2021-242513 34244183
Tawfik P, Arndt P. Lethal hyperammonemia in a CAR-T cell recipient due to ureaplasma pneumonia: a case report of a unique severe complication. BMJ Case Rep. 2021;14(7): e242513.34244183
13. Machado P Arthritis and X-linked agammaglobulinemia Acta Reumatol Port 2008 33 4 464 467 19078863
Machado P, et al. Arthritis and X-linked agammaglobulinemia. Acta Reumatol Port. 2008;33(4):464–7.19078863
14. Hansel TT Haeney MR Thompson RA Primary hypogammaglobulinaemia and arthritis Br Med J (Clin Res Ed) 1987 295 6591 174 175 10.1136/bmj.295.6591.174 3115363
Hansel TT, Haeney MR, Thompson RA. Primary hypogammaglobulinaemia and arthritis. Br Med J (Clin Res Ed). 1987;295(6591):174–5.3115363
15. Barmettler S Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia JAMA Netw Open 2018 1 7 e184169 10.1001/jamanetworkopen.2018.4169 30646343
Barmettler S, et al. Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open. 2018;1(7): e184169.30646343
16. Clough W Septic arthritis and bacteremia due to Mycoplasma resistant to antimicrobial therapy in a patient with systemic lupus erythematosus Clin Infect Dis 1992 15 3 402 407 10.1093/clind/15.3.402 1520784
Clough W, et al. Septic arthritis and bacteremia due to Mycoplasma resistant to antimicrobial therapy in a patient with systemic lupus erythematosus. Clin Infect Dis. 1992;15(3):402–7.1520784
17. Furr PM Taylor-Robinson D Webster AD Mycoplasmas and ureaplasmas in patients with hypogammaglobulinaemia and their role in arthritis: microbiological observations over twenty years Ann Rheum Dis 1994 53 3 183 187 10.1136/ard.53.3.183 8154936
Furr PM, Taylor-Robinson D, Webster AD. Mycoplasmas and ureaplasmas in patients with hypogammaglobulinaemia and their role in arthritis: microbiological observations over twenty years. Ann Rheum Dis. 1994;53(3):183–7.8154936
18. Webster AD Critical dependence on antibody for defence against mycoplasmas Clin Exp Immunol 1988 71 3 383 387 3383447
Webster AD, et al. Critical dependence on antibody for defence against mycoplasmas. Clin Exp Immunol. 1988;71(3):383–7.3383447
19. Taylor-Robinson D Furr PM Webster AD Ureaplasma urealyticum in the immunocompromised host Pediatr Infect Dis 1986 5 6 Suppl S236 S238 10.1097/00006454-198611010-00006 3797323
Taylor-Robinson D, Furr PM, Webster AD. Ureaplasma urealyticum in the immunocompromised host. Pediatr Infect Dis. 1986;5(6 Suppl):S236–8.3797323
20. Stabler S The brief case: mycoplasma hominis extragenital abscess J Clin Microbiol 2021 10.1128/JCM.02343-20 33826523
Stabler S, et al. The brief case: mycoplasma hominis extragenital abscess. J Clin Microbiol. 2021. 10.1128/JCM.02343-20.33826523
21. Su F Identification of sacrococcygeal and pelvic abscesses infected with invasive Mycoplasma hominis by MALDI-TOF MS J Clin Lab Anal 2022 36 4 e24329 10.1002/jcla.24329 35285086
Su F, et al. Identification of sacrococcygeal and pelvic abscesses infected with invasive Mycoplasma hominis by MALDI-TOF MS. J Clin Lab Anal. 2022;36(4): e24329.35285086
22. Waites KB Molecular methods for the detection of Mycoplasma and ureaplasma infections in humans: a paper from the 2011 William Beaumont Hospital Symposium on molecular pathology J Mol Diagn 2012 14 5 437 450 10.1016/j.jmoldx.2012.06.001 22819362
Waites KB, et al. Molecular methods for the detection of Mycoplasma and ureaplasma infections in humans: a paper from the 2011 William Beaumont Hospital Symposium on molecular pathology. J Mol Diagn. 2012;14(5):437–50.22819362
23. Frolund M Comparison between culture and a multiplex quantitative real-time polymerase chain reaction assay detecting Ureaplasma urealyticum and U. parvum PLoS One 2014 9 7 e102743 10.1371/journal.pone.0102743 25047036
Frolund M, et al. Comparison between culture and a multiplex quantitative real-time polymerase chain reaction assay detecting Ureaplasma urealyticum and U. parvum. PLoS One. 2014;9(7): e102743.25047036
24. Stellrecht KA Comparison of multiplex PCR assay with culture for detection of genital mycoplasmas J Clin Microbiol 2004 42 4 1528 1533 10.1128/JCM.42.4.1528-1533.2004 15070999
Stellrecht KA, et al. Comparison of multiplex PCR assay with culture for detection of genital mycoplasmas. J Clin Microbiol. 2004;42(4):1528–33.15070999
25. Hazra A Collison MW Davis AM CDC sexually transmitted infections treatment guidelines, 2021 JAMA 2022 327 9 870 871 10.1001/jama.2022.1246 35230409
Hazra A, Collison MW, Davis AM. CDC sexually transmitted infections treatment guidelines, 2021. JAMA. 2022;327(9):870–1.35230409
26. Workowski KA Sexually transmitted infections treatment guidelines, 2021 MMWR Recomm Rep 2021 70 4 1 187 10.15585/mmwr.rr7004a1 34292926
Workowski KA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1–187.34292926
27. WHO Guidelines for the management of symptomatic sexually transmitted infections 2021 Geneva WHO
WHO. Guidelines for the management of symptomatic sexually transmitted infections. Geneva: WHO; 2021.
28. Krausse R Schubert S In-vitro activities of tetracyclines, macrolides, fluoroquinolones and clindamycin against Mycoplasma hominis and Ureaplasma ssp. isolated in Germany over 20 years Clin Microbiol Infect 2010 16 11 1649 1655 10.1111/j.1469-0691.2010.03155.x 20047607
Krausse R, Schubert S. In-vitro activities of tetracyclines, macrolides, fluoroquinolones and clindamycin against Mycoplasma hominis and Ureaplasma ssp. isolated in Germany over 20 years. Clin Microbiol Infect. 2010;16(11):1649–55.20047607
29. Samra Z Rosenberg S Dan M Susceptibility of Ureaplasma urealyticum to tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin J Chemother 2011 23 2 77 79 10.1179/joc.2011.23.2.77 21571622
Samra Z, Rosenberg S, Dan M. Susceptibility of Ureaplasma urealyticum to tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin. J Chemother. 2011;23(2):77–9.21571622
30. Niccoli Asabella A Role of (18)F-FDG PET/CT in the evaluation of response to antibiotic therapy in patients affected by infectious spondylodiscitis Hell J Nucl Med 2015 18 Suppl 1 17 22 26665207
Niccoli Asabella A, et al. Role of (18)F-FDG PET/CT in the evaluation of response to antibiotic therapy in patients affected by infectious spondylodiscitis. Hell J Nucl Med. 2015;18(Suppl 1):17–22.26665207
31. Pijl JP PET/CT imaging for personalized management of infectious diseases J Pers Med 2021 11 2 133 10.3390/jpm11020133 33669375
Pijl JP, et al. PET/CT imaging for personalized management of infectious diseases. J Pers Med. 2021;11(2):133.33669375
32. Divithotewala C Mycoplasma hominis and Ureaplasma urealyticum infections in the immediate post-lung transplant period: a case series and literature review Transpl Infect Dis 2023 25 3 e14058 10.1111/tid.14058 36974436
Divithotewala C, et al. Mycoplasma hominis and Ureaplasma urealyticum infections in the immediate post-lung transplant period: a case series and literature review. Transpl Infect Dis. 2023;25(3): e14058.36974436
33. Farfour E Vasse M Vallee A Mollicutes-related infections in thoracic surgery including lung and heart transplantation: a systematic review J Heart Lung Transplant 2024 43 1 169 180 10.1016/j.healun.2023.09.023 37797819
Farfour E, Vasse M, Vallee A. Mollicutes-related infections in thoracic surgery including lung and heart transplantation: a systematic review. J Heart Lung Transplant. 2024;43(1):169–80.37797819
34. Tam PCK Risk factors, management, and clinical outcomes of invasive Mycoplasma and Ureaplasma infections after lung transplantation Am J Transplant 2024 24 4 641 652 10.1016/j.ajt.2023.08.019 37657654
Tam PCK, et al. Risk factors, management, and clinical outcomes of invasive Mycoplasma and Ureaplasma infections after lung transplantation. Am J Transplant. 2024;24(4):641–52.37657654
35. Steuer A Common variable immunodeficiency presenting as a Mycoplasma hominis septic arthritis J Infect 1996 33 3 235 237 10.1016/S0163-4453(96)92441-X 8945717
Steuer A, et al. Common variable immunodeficiency presenting as a Mycoplasma hominis septic arthritis. J Infect. 1996;33(3):235–7.8945717
36. Franz A Mycoplasmal arthritis in patients with primary immunoglobulin deficiency: clinical features and outcome in 18 patients Br J Rheumatol 1997 36 6 661 668 10.1093/rheumatology/36.6.661 9236676
Franz A, et al. Mycoplasmal arthritis in patients with primary immunoglobulin deficiency: clinical features and outcome in 18 patients. Br J Rheumatol. 1997;36(6):661–8.9236676
37. Heilmann C Treatment of resistant mycoplasma infection in immunocompromised patients with a new pleuromutilin antibiotic J Infect 2001 43 4 234 238 10.1053/jinf.2001.0910 11869060
Heilmann C, et al. Treatment of resistant mycoplasma infection in immunocompromised patients with a new pleuromutilin antibiotic. J Infect. 2001;43(4):234–8.11869060
38. Sendi P Zimmerli W Michot M Spondylitis and arthritis due to Mycoplasma hominis: the case for awareness in undefined pleuropneumonia Clin Infect Dis 2004 39 8 1250 1251 10.1086/424453 15486853
Sendi P, Zimmerli W, Michot M. Spondylitis and arthritis due to Mycoplasma hominis: the case for awareness in undefined pleuropneumonia. Clin Infect Dis. 2004;39(8):1250–1.15486853
39. MacKenzie CR Fatal outcome of a disseminated dual infection with drug-resistant Mycoplasma hominis and Ureaplasma parvum originating from a septic arthritis in an immunocompromised patient Int J Infect Dis 2010 14 Suppl 3 e307 e309 10.1016/j.ijid.2010.02.2253 20554466
MacKenzie CR, et al. Fatal outcome of a disseminated dual infection with drug-resistant Mycoplasma hominis and Ureaplasma parvum originating from a septic arthritis in an immunocompromised patient. Int J Infect Dis. 2010;14(Suppl 3):e307–9.20554466
40. Wynes J Subtalar joint septic arthritis in a patient with hypogammaglobulinemia J Foot Ankle Surg 2013 52 2 242 248 10.1053/j.jfas.2012.10.012 23153784
Wynes J, et al. Subtalar joint septic arthritis in a patient with hypogammaglobulinemia. J Foot Ankle Surg. 2013;52(2):242–8.23153784
41. Sato H Hypogammaglobulinemic patient with polyarthritis mimicking rheumatoid arthritis finally diagnosed as septic arthritis caused by Mycoplasma hominis Intern Med 2012 51 4 425 429 10.2169/internalmedicine.51.6058 22333381
Sato H, et al. Hypogammaglobulinemic patient with polyarthritis mimicking rheumatoid arthritis finally diagnosed as septic arthritis caused by Mycoplasma hominis. Intern Med. 2012;51(4):425–9.22333381
42. Nulens E A disseminated Mycoplasma hominis infection in a patient with an underlying defect in humoral immunity Infection 2016 44 3 379 381 10.1007/s15010-015-0859-6 26546371
Nulens E, et al. A disseminated Mycoplasma hominis infection in a patient with an underlying defect in humoral immunity. Infection. 2016;44(3):379–81.26546371
43. Ali GA An enemy in shadows-Mycoplasma hominis septic arthritis and iliopsoas abscess: case report and review of the literature IDCases 2021 26 e01260 10.1016/j.idcr.2021.e01260 34485081
Ali GA, et al. An enemy in shadows-Mycoplasma hominis septic arthritis and iliopsoas abscess: case report and review of the literature. IDCases. 2021;26: e01260.34485081
44. Bozo N Mycoplasma hominis septic arthritis in a patient with hypogammaglobinaemia and rheumatoid arthritis BMJ Case Rep 2021 14 1 e237798 10.1136/bcr-2020-237798 33468512
Bozo N, et al. Mycoplasma hominis septic arthritis in a patient with hypogammaglobinaemia and rheumatoid arthritis. BMJ Case Rep. 2021;14(1): e237798.33468512
45. Sadhar B Mycoplasma hominis: a rare case of acute otitis media and facial nerve paralysis Ear Nose Throat J 2022 10.1177/01455613221113814 36041826
Sadhar B, et al. Mycoplasma hominis: a rare case of acute otitis media and facial nerve paralysis. Ear Nose Throat J. 2022. 10.1177/01455613221113814.36041826
